Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes mellitus~* Patients on diet and exercise regimen who are pre-treated with any insulin therapy alone or in combination with 1 oral antidiabetic drug for at least 12 weeks prior to screening~* Fasting C-peptide must be \> 0.5 ng/mL~* HbA1c at screening in Patients who are treated with insulin alone must be \>=7.5% and \<=10.0%~* HbA1c in Patients who are treated with insulin with 1 oral antidiabetic drug (OAD) must be \>=7.0% and \<=9.5% at screening, and \>=7.5% and \<=10.0% at placebo run-in period~* Age at informed consent must be \>=20 and \<75 years~* BMI at screening must be \>22 and \<=40 kg/m2~* Further inclusion criteria apply~Exclusion criteria:~* Patients who experience uncontrolled hyperglycaemia before randomization~* Patients who are treated with sulfonylurea whose dose is more than a half of daily maximum approval dose, glucagon-like peptide-1 (GLP-1) analogue, thiazolidinedione and sodium-glucose co-transporter 2 (SGLT-2) inhibitor~* Patients with recent cardiovascular and/or stroke events~* Patients with hepatic and/or renal dysfunction~* Patients who received anti-obesity drugs or other treatment leading to unstable body weight~* Patients who have known allergy or hypersensitivity to insulin and/or empagliflozin~* Pre-menopausal women who are nursing or pregnant~* Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- empagliflozin 10 mg (Type: EXPERIMENTAL): None
- empagliflozin 25 mg (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).